Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients

Annals of Surgical Oncology

Volumn 15, Issue 6, 2008, Pages 1617-1624

  Toiyama, Yuji ^a   Miki, Chikao ^a   Inoue, Yasuhiro ^a   Okugawa, Yoshinaga ^a   Koike, Yuki ^a   Yokoe, Takeshi ^a   Tanaka, Kouji ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

CEA; Colorectal cancer; Prognostic factor; sICAM 1; Stage II

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 43449119809     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9874-5     Document Type: Article

References (32)

1. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31A:1255-63
2. Wein A, Hahn EG, Merkel S, et al. Adjuvant chemotherapy for stage II colon cancer. Eur J Surg Oncol 2000; 26:730-2
3. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47:624-30
4. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965; 121:439-62
5. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270:943-7
6. Kimura Y, Fujieda S, Takabayashi T, et al. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett 2000; 155:163-8
7. Smith ME, Thomas JA. Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue. J Clin Pathol 1990; 43:893-900
8. Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147:3788-93
9. Banks RE, Gearing AJ, Hemingway IK, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 1993; 68:122-4
10. Velikova G, Banks RE, Gearing A, et al. Serum concentration of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 1998; 77:1857-63
11. Giavazzi R, Chirivi RG, Garofalo A, et al. Soluble intercellular adhesion molecule-1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 1992; 52:2628
12. Viac J, Vincent C, Palacio S, et al. Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels. Eur J Cancer 1996; 32A:447
13. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37:2392
14. Liu YZ, Chen B, She XD. A clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with gastric cancer. World J Gastroenterol 1998; 4:225
15. Nakata B, Hori T, Sunami T, et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000; 6:1175
16. Zhang GJ, Adachi I. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol 1999; 14:71
17. Duffy MJ. CEA as a marker for colorectal cancer: is it clinically useful. Clin Chem 2001; 47:624-30
18. Aster VB, Coller FA. The prognosis significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 192:846-50
19. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998; 78:40-5
20. Becker JC, Dummer R, Hartmann AA, et al. Shedding of ICAM-1 from human melanoma cell lines induced by INF-gamma and TNF-alpha: functional consequences on cell-mediated cytotoxicity. J Immunol 1991; 147:4398
21. Rokhlin OW, Cohen MB. Soluble forms of CD44 and CD54 (ICAM-1) cellular adhesion molecules are released by human prostatic cancer cell lines. Cancer Lett 1996; 107:29
22. Araki T, Miki C, Kusunoki M. Biological implications of circulating soluble intercellular adhesion molecule-1 in colorectal cancer patients. Scand J Gastroenterol 2001; 36:399-404
23. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004; 15:91-8
24. Makgoba MW, Sanders ME, Ginther Luce GE, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988; 18:637-40
25. Chong AS, Boussy IA, Jiang XL, et al. CD54/ ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol 1994; 157:92-105
26. Kamezaki S, Kurozawa Y, Iwai N, et al. Serum levels of soluble ICAM-1 and VCAM-1 predict pre-clinical cancer. Eur J Cancer 2005; 41:2355-9
27. Nakata B, Hori T, Sunami T, et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000; 6:1175-9
28. Mulcahy HE, Duffy MJ, Gibbons D, et al. Urokinase-type plasminogen activator andoutcome in Dukes' B colorectal cancer. Lancet 1994; 344:583-84
29. Kay EW, Mulcahy H, Walsh CB, et al. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994; 25:455-61
30. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-46
31. Dorudi S, Hanby AM, Poulsom R, et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995; 71:614-6
32. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14:1026-38